: Beta-lactams are extensively used antibiotics known for their safety and effectiveness. The rise in patients who receive care in outpatient settings has increased the interest in subcutaneous administration (SA). The aim of the study is to assess the safety and pharmacokinetic (PK) profiles of SA of beta-lactams compared with other routes. The protocol was registered in the PROSPERO database and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed. Online databases were searched, and the quality of the eligible studies was assessed. The data extracted related to adverse events (AEs) and PK were summarised narratively. Sixteen studies were included. The reported AEs were generally mild, localised, and temporary. Although SA and intravenous administration had similar PK profiles, SA resulted in lower peak drug concentrations and slower absorption. Heterogeneity in the populations, medication delivery, outcome measures, and methodological quality emerged across the studies. The mild severity of AEs suggests that SA is a viable route. Additionally, SA appears to demonstrate effective PK profiles and delays drug release, with potential to reduce the dosing frequency and prolong the therapeutic effects. SA of beta-lactams is a promising viable alternative to intravenous administration, potentially enhancing treatment in the outpatient and long-term care settings.

Safety and Pharmacokinetic Profiles of Subcutaneous Administration of Beta-Lactams: A Systematic Review

Moreal, Chiara
Primo
;
Chiappinotto, Stefania;Lanini, Simone;Montanari, Luca;Palese, Alvisa
Penultimo
;
Tascini, Carlo
Ultimo
2024-01-01

Abstract

: Beta-lactams are extensively used antibiotics known for their safety and effectiveness. The rise in patients who receive care in outpatient settings has increased the interest in subcutaneous administration (SA). The aim of the study is to assess the safety and pharmacokinetic (PK) profiles of SA of beta-lactams compared with other routes. The protocol was registered in the PROSPERO database and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed. Online databases were searched, and the quality of the eligible studies was assessed. The data extracted related to adverse events (AEs) and PK were summarised narratively. Sixteen studies were included. The reported AEs were generally mild, localised, and temporary. Although SA and intravenous administration had similar PK profiles, SA resulted in lower peak drug concentrations and slower absorption. Heterogeneity in the populations, medication delivery, outcome measures, and methodological quality emerged across the studies. The mild severity of AEs suggests that SA is a viable route. Additionally, SA appears to demonstrate effective PK profiles and delays drug release, with potential to reduce the dosing frequency and prolong the therapeutic effects. SA of beta-lactams is a promising viable alternative to intravenous administration, potentially enhancing treatment in the outpatient and long-term care settings.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11390/1293644
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact